Mobocertinib

105 interactions 10 explained in plain English

Also sold as: Exkivity

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ketoconazole Topical Lefamulin Medroxyprogesterone Clindamycin Topical Metronidazole Topical Oxaliplatin Injection

2 Contraindicated 100 Major 3 Moderate

All (105) Contraindicated (2) Major (100) Moderate (3)

Contraindicated

Mobocertinib Ketoconazole Topical Extina® Foam Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Mobocertinib Lefamulin Xenleta Increased risk of QT interval prolongation Details

Major

Mobocertinib Acetaminophen And Codeine Capital® & Codeine Explained Reduced codeine and morphine exposure, reduced opioid efficacy and precipitation of opioid withdrawal Details Mobocertinib Clindamycin ANTIROBE Explained Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Mobocertinib Sertraline Explained An increased risk of QT interval prolongation Details Mobocertinib Buprenorphine Belbuca Explained An increased risk of QT interval prolongation Details Mobocertinib Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Mobocertinib Colchicine Colcrys Explained Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Abemaciclib Verzenio Explained Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Acalabrutinib Calquence Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Amisulpride Injection Barhemsys An increased risk of QT interval prolongation Details Mobocertinib Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Mobocertinib Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Mobocertinib Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Mobocertinib Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Mobocertinib Atogepant Qulipta Reduced atogepant exposure Details Mobocertinib Azithromycin AzaSite An increased risk of QT interval prolongation Details Mobocertinib Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Mobocertinib Alfuzosin UroXatral An increased risk of QT interval prolongation Details Mobocertinib Amlodipine Amvaz® Reduced amLODIPine exposure Details Mobocertinib Anagrelide Agrylin An increased risk of QT interval prolongation Details Mobocertinib Axitinib Inlyta Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Bedaquiline Sirturo An increased risk of QT interval prolongation Details Mobocertinib Bosutinib Bosulif Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Brigatinib Alunbrig Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Chloroquine Aralen® An increased risk of QT interval prolongation Details Mobocertinib Clindamycin Injection ANTIROBE Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Clindamycin Topical C/T/S® Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Clindamycin Vaginal Cleocin Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Cobimetinib Cotellic Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Cyclosporine Injection Atopica Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Cyclosporine Ophthalmic Cequa Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Dasatinib Phyrago Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure; QT interval prolongation Details Mobocertinib Degarelix Injection Firmagon An increased risk of QT interval prolongation Details Mobocertinib Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Mobocertinib Dihydroergotamine Injection DHE-45® Injection Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Dihydroergotamine Nasal Spray Migranal Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Disopyramide Norpace An increased risk of QT interval prolongation Details Mobocertinib Docetaxel Beizray Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.